{
    "clinical_study": {
        "@rank": "16670", 
        "arm_group": {
            "arm_group_label": "Basic science (interferon gamma and MHC expression)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in\n      treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth\n      of tumor cells."
        }, 
        "brief_title": "Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma", 
        "condition": [
            "Adult Liposarcoma", 
            "Adult Synovial Sarcoma", 
            "Recurrent Adult Soft Tissue Sarcoma", 
            "Stage IA Adult Soft Tissue Sarcoma", 
            "Stage IB Adult Soft Tissue Sarcoma", 
            "Stage IIA Adult Soft Tissue Sarcoma", 
            "Stage IIB Adult Soft Tissue Sarcoma", 
            "Stage III Adult Soft Tissue Sarcoma", 
            "Stage IV Adult Soft Tissue Sarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Liposarcoma", 
                "Sarcoma, Synovial", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine whether systemic administration of interferon (IFN) gamma (recombinant\n      interferon gamma) will increase class I major histocompatibility complex (MHC) expression in\n      synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) tumors.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine whether systemic administration of IFN gamma will increase class II MHC\n      expression in SS and MRCL tumors.\n\n      II. To examine changes in the immune response to MRCL and SS by examining changes in the\n      immune infiltrates, antibody response and antigen specific T cell response before and after\n      IFN gamma treatment.\n\n      OUTLINE:\n\n      Patients receive recombinant interferon gamma subcutaneously (SC) every 7 days for 4 weeks\n      before surgery or thrice weekly for 2 weeks before surgery.\n\n      After completion of study, patients are followed up at 2 weeks post-surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A diagnosis of synovial sarcoma and myxoid/round cell liposarcoma\n\n          -  All patients must have consulted with a surgical provider and are being considered\n             for resection or biopsy of their tumor\n\n          -  Available prior biopsy or tumor resection specimen of lesion to be resected (the\n             target lesion) or biopsied confirming the diagnosis of that lesion and with tissue\n             available for class I MHC staining\n\n          -  Zubrod performance status of '0-2'\n\n          -  No treatment with systemic anti-cancer treatment (chemotherapy or biologics) within 2\n             weeks of starting interferon gamma\n\n          -  Patients must have an electrocardiogram (EKG) performed within 2 weeks of enrollment;\n             patients with a history of cardiac disease or abnormal EKG must have had a normal\n             stress test within 180 days of starting IFN gamma\n\n          -  Must have been off metformin for at least 2 weeks prior to starting IFN gamma\n\n          -  No use of full dose, therapeutic anti-coagulation; however, low dose warfarin for\n             catheter prophylaxis or acetylsalicylic acid are acceptable\n\n          -  No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of\n             starting IFN gamma\n\n        Exclusion Criteria:\n\n          -  Active infection requiring oral or intravenous antibiotics\n\n          -  Pregnant women, nursing mothers, men or women of reproductive ability who are\n             unwilling to use effective contraception or abstinence; women of childbearing\n             potential must have a negative pregnancy test within two weeks prior to entry\n\n          -  Serum creatinine > 1.5 mg/dL or glomerular filtration rate < 50\n\n          -  Serum glutamic oxaloacetic transaminase (SGOT) > 150 IU or > 3 x upper limit of\n             normal\n\n          -  Bilirubin > 1.6 mg/dL\n\n          -  Prothrombin time > 1.5 x control\n\n          -  Untreated central nervous system (CNS) metastasis; once CNS metastasis have been\n             treated these patients may participate if they are otherwise good trial candidates\n\n          -  Current treatment with steroids (must be discontinued 1 week before starting IFN\n             gamma)\n\n          -  Hemoglobin A1C > 8.5%\n\n          -  Uncontrolled hypertension, blood pressure (BP) > 150/100mmHg; patients with elevated\n             BP may enroll once BP is corrected\n\n          -  Prior cancer/testis antigen 1B (NY-ESO-1) specific T cell therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957709", 
            "org_study_id": "2705.00", 
            "secondary_id": [
                "NCI-2013-01779", 
                "2705.00", 
                "P30CA015704", 
                "K12CA076930"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Basic science (interferon gamma and MHC expression)", 
                "description": "Given SC", 
                "intervention_name": "recombinant interferon gamma", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Actimmune", 
                    "gamma interferon", 
                    "IFN-G"
                ]
            }, 
            {
                "arm_group_label": "Basic science (interferon gamma and MHC expression)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-gamma", 
                "Interferons"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "last_name": "Seth Pollack", 
                "phone": "206-667-6629"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
            }, 
            "investigator": {
                "last_name": "Seth Pollack", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Seth Pollack", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "It is estimated that the true mean change in expression following IFN gamma will be 50% (for homogenous expression) with a standard deviation of 30%. Seven patients will provide 95% power to observe a change in expression (before IFN vs. after IFN) that is statistically significantly (at the 2-sided significance level of .05) different from a change of zero.", 
            "measure": "Change in class I MHC expression after treatment with IFN gamma as determined by immunohistochemistry (IHC)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to up to 2 weeks post-surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}